Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 6048

Artificial Intelligence’s biggest Problems is their inability to keep on learning after they’ve completed their training. But now, Google’s Deepmind has created a Meta-Learning AI which keeps on learning and improving indefinitely without any Human supervision. Deepmind created the AI Game: Alchemy, which is a chemistry-based game for AI Agents to play and improve in. But Artificial Intelligence improving without limits also puts some concerns into AI researchers focused on deep learning.

There has been rapidly growing interest in meta-learning as a method for increasing the flexibility and sample efficiency of reinforcement learning.
–

If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile
–
TIMESTAMPS:
00:00 The Ultimate kind of AI?
01:02 What is Meta-Learning in AI?
02:24 Alchemy AI Agent.
04:02 How Meta-Learning solved AI Problems.
06:32 What are the dangers of this AI?
08:29 Last Words.
–
#ai #metalearning #singularity

Read more | >

I may have already posted about this, but this is more data from The Lancet.

Background.

Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.

Methods.

This placebo-controlled, randomised, adaptive platform trial done among high-risk symptomatic Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients from 11 clinical sites in Brazil with a known risk factor for progression to severe disease. Patients were randomly assigned (1:1) to either fluvoxamine (100 mg twice daily for 10 days) or placebo (or other treatment groups not reported here). The trial team, site staff, and patients were masked to treatment allocation. Our primary outcome was a composite endpoint of hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19 up to 28 days post-random assignment on the basis of intention to treat. Modified intention to treat explored patients receiving at least 24 h of treatment before a primary outcome event and per-protocol analysis explored patients with a high level adherence (80%). We used a Bayesian analytic framework to establish the effects along with probability of success of intervention compared with placebo. The trial is registered at ClinicalTrials dot gov (NCT04727424) and is ongoing.

Continue reading “Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial” | >

Creating a world where no woman has to die giving life — temitayo erogbogbo, global advocacy director, MSD for mothers, merck sharp & dohme.

Mr. Temitayo (Tayo) Erogbogbo, is Global Advocacy Director of MSD for Mothers (https://www.msdformothers.com/), at Merck Sharp & Dohme.

Tayo has two decades of combined private sector and international development experience, 13 years of which was spent in the pharmaceutical industry in multiple roles across community relations, government affairs, marketing and sales.

Continue reading “Mr. Temitayo Erogbogbo, Global Advocacy Director, MSD for Mothers (Merck Sharp & Dohme)” | >

In explosive development, China has been threatening U.S. executives, companies and business groups in recent weeks to fight against China-related bills in the U.S. Congress. According to Reuters, letters from China’s embassy in Washington have pressed executives to urge members of Congress to alter or drop specific bills that seek to enhance U.S. competitiveness.

Follow our Telegram Channel — https://t.me/tfiglobal.
Please support us on Patreon — https://www.patreon.com/tfiglobal

Read more | >

WIRED sat down with West to sift fantasy from reality and pin down what XR is actually good at. And it may come as a surprise that a lot of it relies on collecting a lot of data. The following interview is a transcript of our conversation, lightly edited for clarity and length.

WIRED: So let’s start with sort of an ontological question. There’s been this idea that we’ll be in or go to the metaverse, or several metaverses, which tech companies posit will exist in VR or AR. Do you see VR and AR as being more of a tool or a destination?

Timoni West: That’s a great question. I would actually say neither. I see XR as one of the many different mediums you could choose to work in. For example, we actually have an AR mobile companion app [in beta] that allows you to scan a space and gray box it out, put down objects, automatically tag things. So I’m using AR to do the things that AR is best for. I’ll use VR to do the things that VR is best for, like presence, being able to meet together, sculpt, or do anything that’s, you know, sort of intrinsically 3D.

Although the colonization of Venus seems like a lost cause to many, it appears that the people at NASA are very optimistic about their plans to colonize it! Subscribe to Futurity for more space news.

#nasa #space #venus.

Here at Futurity, we scour the globe for all the latest tech releases, news and info just so you don’t have to! Covering everything from cryptocurrency to robotics, small startups to multinational corporations like Tesla and Jeff Bezos to Elon Musk and everything in between!

Read more | >